Pozelimab
Pozelimab is a fully human monoclonal antibody that inhibits complement component C5 by blocking its cleavage into C5a and C5b, thereby preventing formation of the terminal complement complex (membrane attack complex) and its associated inflammatory and cytolytic effects. It is approved for the treatment of CD55-deficient protein-losing enteropathy (CHAPLE disease) and is under investigation for other complement-mediated disorders including age-related macular degeneration.
Therapeutic Areas
Mechanism of Action
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
Pozelimab is a fully human monoclonal antibody that inhibits complement component C5 by blocking its cleavage into C5a and C5b, thereby preventing formation of the terminal complement complex (membrane attack complex) and its associated inflammatory and cytolytic effects. It is approved for the treatment of CD55-deficient protein-losing enteropathy (CHAPLE disease) and is under investigation for other complement-mediated disorders including age-related macular degeneration.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Pozelimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298086. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pozelimab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pozelimab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pozelimab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pozelimab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pozelimab"></drugfyi-drug>